Navigation Links
nContact's Cardiac Ablation Technology to be Presented in Two Noteworthy Posters at Boston Atrial Fibrillation Symposium 2012

MORRISVILLE, N.C., Jan. 9, 2012 /PRNewswire/ -- nContact, Inc., the leading innovator in epicardial ablation devices, today announced its technology will be presented by physicians in two posters at the 17th Annual International Boston Atrial Fibrillation Symposium, January 12-14 in Boston, Massachusetts.  nContact will be showcasing its Numeris® Coagulation System with VisiTrax® and next generation EPi-Sense™ Coagulation System at its Boston AF Symposium booth #301.

nContact's epicardial ablation device integrates suction, perfusion and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart. Access to the posterior of the atrium is achieved with unique access through the diaphragm with a SUBTLE (sub-thoracic, total endoscopic) approach for minimally invasive, closed-chest epicardial ablation.  

The technology will be presented in the following posters on Friday, January 13, 2012 available from 7:30 am until 6:30 pm:

  • Poster # 10 titled: "Prospective Reveal® XT Outcomes for the Convergent Atrial Fibrillation Ablation Procedure"
    Evaluates long-term outcomes of a multidisciplinary ablation procedure to treat persistent or longstanding persistent AF, as monitored by Reveal XT technology (Medtronic); presented by Borut Gersak, MD, of University Medical Center Ljubljana, Ljubljiana, Slovenia.
  • Poster #20 titled: "Multicenter Retrospective Outcomes for the Treatment of Atrial Fibrillation Using the Multidisciplinary Convergent Procedure"
    Examines outcomes of closed chest AF ablation procedure on patients with persistent or longstanding persistent AF across four U.S. sites; presented by Dr. Keith Golden of St. Vincent Hospital, Indianapolis, IN.
  • About nContact, Inc.
    nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF). The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

    To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States. nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.

    The Numeris™ and EPi-Sense™ Coagulation Systems with VisiTrax® have CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of atrial fibrillation and atrial flutter. For more information, please visit www.ncontactinc.comMedia Contacts

     Beth Rose

    Kimberly MuscaranContact, Inc

    The Ruth Group T (919)655-1566 

    T (646)

    SOURCE nContact, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Ikaria® Commences Global Registration Trial for Bioabsorbable Cardiac Matrix
    2. FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure
    3. Australias Sporting Clubs Select Cardiac Science AEDs
    4. Roche, ChanTest Collaborate for Preclinical Cardiac Safety Testing of Drug Compounds Using iCell Cardiomyocytes and xCELLigence RTCA Cardio Instrument
    5. MedSolutions Launches Implantable Cardiac Defibrillator Program to Reduce Unnecessary Surgeries
    6. Philips Launches HeartStart FR3 Automated External Defibrillator for Professional Responders Treating Victims of Sudden Cardiac Arrest
    7. MedSolutions Announces Program to Reduce Unnecessary Implantable Cardiac Defibrillator Surgeries
    8. Cardiac Dimensions Announces Presentation of Two-Year Efficacy Data From TITAN Clinical Trial
    9. Implantable Cardioverter Defibrillators and Cardiac Resynchronization Therapy-Defibrillators - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
    10. "Today" Show, "Fox & Friends" Put Spotlight on Sudden Cardiac Arrest
    11. Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™
    Post Your Comments:
    (Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
    (Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
    (Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
    (Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
    (Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
    (Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
    (Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
    Breaking Medicine News(10 mins):